{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:14:30Z","timestamp":1793531670020,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-018-1047-7","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T05:02:22Z","timestamp":1548046942000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Glasdegib: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"issue":"10","key":"1047_CR1","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","volume":"119","author":"DA Irvine","year":"2012","unstructured":"Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119(10):2196\u2013204.","journal-title":"Blood."},{"key":"1047_CR2","unstructured":"Pfizer. US FDA approves DAURISMO\u2122 (glasdegib) for adult patients with newly-diagnosed acute myeloid leukemia (AML) for whom intensive chemotherapy is not an option. 2018. \n                    http:\/\/www.pfizer.com\/\n                    \n                  . Accessed 23 Nov 2018."},{"key":"1047_CR3","unstructured":"Pfizer. DaurismoTM (glasdegib) tablets, for oral use: US prescribing information. 2018. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 26 Nov 2018."},{"key":"1047_CR4","unstructured":"US FDA. FDA approves new treatment for patients with acute myeloid leukemia. 2018. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 23 Nov 2018."},{"key":"1047_CR5","unstructured":"US FDA. Orphan drug designations and approvals. 2017. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/listResult.cfm\n                    \n                  . Accessed 20 Dec 2018."},{"key":"1047_CR6","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: glasdegib maleate for the treatment of acute myeloid leukaemia. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 23 Nov 2018."},{"key":"1047_CR7","unstructured":"Pfizer. New phase 2 results show investigational compound glasdegib improved overall survival in acute myeloid leukemia and high-risk myelodysplastic syndrome [media release]. \n                    http:\/\/www.pfizer.com\n                    \n                  . Accessed 3 Dec 2016."},{"issue":"8","key":"1047_CR8","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","volume":"2","author":"G Martinelli","year":"2015","unstructured":"Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2(8):e339\u201346.","journal-title":"Lancet Haematol."},{"issue":"5","key":"1047_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-14-1116","volume":"21","author":"AJ Wagner","year":"2015","unstructured":"Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(5):1044\u201351.","journal-title":"Clin Cancer Res."},{"key":"1047_CR10","doi-asserted-by":"crossref","unstructured":"Lancet JE, Komrokji RS, Sweet KL, et al. Phase 2 trial of smoothened (SMO) inhibitor PF-04449913 (PF-04) in refractory myelodysplastic syndromes (MDS) [abstract]. In: 58th American Society of Hematology Annual Meeting. 2016.","DOI":"10.1182\/blood.V128.22.3174.3174"},{"issue":"Suppl 1","key":"1047_CR11","first-page":"S87","volume":"45","author":"N Shaik","year":"2018","unstructured":"Shaik N, Da Costa LM, Hee B, et al. A thorough QT study to evaluate the effect of glasdegib on cardiac repolarization in healthy adult subjects [abstract no. T-092]. J Pharmacokinet Pharmacodyn. 2018;45(Suppl 1):S87.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"Suppl 1","key":"1047_CR12","first-page":"S78","volume":"103","author":"S Lin","year":"2018","unstructured":"Lin S, Shaik M, Ruiz A. Population pharmacokinetics of glasdegib in patients with advanced hematologic and solid tumors [abstract no. PII-086]. Clin Pharmacol Ther. 2018;103(Suppl 1):S78.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1047_CR13","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","volume":"24","author":"MR Savona","year":"2018","unstructured":"Savona MR, Pollyea DA, Stock W, et al. Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res. 2018;24(10):2294\u2013303.","journal-title":"Clin Cancer Res."},{"issue":"12","key":"1047_CR14","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/00498254.2016.1261307","volume":"47","author":"JL Lam","year":"2017","unstructured":"Lam JL, Vaz A, Hee B, et al. Metabolism, excretion and pharmacokinetics of [14C] glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017;47(12):1064\u201376.","journal-title":"Xenobiotica."},{"issue":"8","key":"1047_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/cas.13285","volume":"108","author":"Y Minami","year":"2017","unstructured":"Minami Y, Minami H, Miyamoto T, et al. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. Cancer Sci. 2017;108(8):1628\u201333.","journal-title":"Cancer Sci."},{"key":"1047_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018. \n                    https:\/\/doi.org\/10.1038\/s41375-018-0312-9\n                    \n                  .","journal-title":"Leukemia"},{"key":"1047_CR17","unstructured":"Tremblay G, Arondekar B, Chan G, et al. Covariate adjusted indirect treatment comparison (ITC) of glasdegib plus low dose Ara-C versus a hypomethylating agent for acute myeloid leukemia patients ineligible for intensive chemotherapy. In: 59th American Society of Hematology Annual Meeting. 2017."},{"issue":"11","key":"1047_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Douglas Smith B, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93(11):1301\u201310.","journal-title":"Am J Hematol."},{"issue":"21","key":"1047_CR19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V118.21.424.424","volume":"118","author":"C Jamieson","year":"2011","unstructured":"Jamieson C, Cortes JE, Oehler V, et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract no. 424]. Blood. 2011;118(21):424.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1047_CR20","first-page":"73","volume":"101","author":"U Borate","year":"2016","unstructured":"Borate U, Smith BD, Gore S, et al. Phase 1b study of glasdegib (PF-04449913) in combination with azacitidine in patients with higher risk myelodysplastic syndrome, oligoblastic acute myeloid leukemia, or chronic myelomonocytic leukemia [abstract no. P255]. Haematologica. 2016;101(Suppl 1):73\u20134.","journal-title":"Haematologica"},{"key":"1047_CR21","doi-asserted-by":"crossref","unstructured":"Cortes JE, Dombret H, Merchant AA, et al. Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia [abstract no. TPS7073]. J Clin Oncol. 2018;36(15 Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7073"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1047-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1047-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1047-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:13:01Z","timestamp":1579565581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1047-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1047-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"21 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}